- Home
- TERN vs OCGN Comparison
TERN vs OCGN Comparison
Compare TERN & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TERN
- OCGN
- Stock Information
- Founded
- TERN 2017
- OCGN 2013
- Country
- TERN United States
- OCGN United States
- Employees
- TERN N/A
- OCGN N/A
- Industry
- TERN Biotechnology: Pharmaceutical Preparations
- OCGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TERN Health Care
- OCGN Health Care
- Exchange
- TERN Nasdaq
- OCGN Nasdaq
- Market Cap
- TERN 321.4M
- OCGN 278.3M
- IPO Year
- TERN 2021
- OCGN N/A
- Fundamental
- Price
- TERN $3.80
- OCGN $1.03
- Analyst Decision
- TERN Buy
- OCGN Strong Buy
- Analyst Count
- TERN 5
- OCGN 3
- Target Price
- TERN $15.63
- OCGN $6.00
- AVG Volume (30 Days)
- TERN 932.0K
- OCGN 8.5M
- Earning Date
- TERN 08-04-2025
- OCGN 08-07-2025
- Dividend Yield
- TERN N/A
- OCGN N/A
- EPS Growth
- TERN N/A
- OCGN N/A
- EPS
- TERN N/A
- OCGN N/A
- Revenue
- TERN N/A
- OCGN $4,522,000.00
- Revenue This Year
- TERN N/A
- OCGN N/A
- Revenue Next Year
- TERN N/A
- OCGN N/A
- P/E Ratio
- TERN N/A
- OCGN N/A
- Revenue Growth
- TERN N/A
- OCGN N/A
- 52 Week Low
- TERN $1.87
- OCGN $0.52
- 52 Week High
- TERN $11.40
- OCGN $1.98
- Technical
- Relative Strength Index (RSI)
- TERN 61.74
- OCGN 55.00
- Support Level
- TERN $3.66
- OCGN $0.95
- Resistance Level
- TERN $4.30
- OCGN $1.15
- Average True Range (ATR)
- TERN 0.31
- OCGN 0.11
- MACD
- TERN -0.01
- OCGN -0.02
- Stochastic Oscillator
- TERN 59.28
- OCGN 22.62
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.
About OCGN Ocugen Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").